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Abstract   
Introduction: Latin American and Mediterranean (LAM) is a family of Mycobacterium 
tuberculosis (M. tuberculosis). Drug resistant in M. tuberculosis LAM family is a major 
problem in the world population. Our objective of this study was to determine the prevalence 
of M. tuberculosis LAM family with multi-drug resistant (MDR) in the worldwide by a meta-
analysis and systematic review. 
Materials and methods: Data sources of this study were 68 original articles (2001-2012) 
which were published in different databases. Research articles with full text in English were 
selected. Review articles, congress abstracts, studies that were reported in languages other than 
English and also studies that were not available for us in abstract or full text were excluded. 
Data that were obtained from prevalence and occurrence rate of MDR M. tuberculosis LAM 
family were analyzed using meta-analysis random effects models with software package Meta 
R, Version 2.13 (P < 0.10). 
Results: During 10 years, lowest rate of prevalence was observed in 2010 and 2006 (95% CI: 
5.91%-6.95%) and highest prevalence rate was in 2006 (95% CI: 17.48%- 24.05%). prevalence 
of MDR- M. tuberculosis analysis showed positive MDR between them (95% CI: 10.30%-
11.23%). Prevalence for negative MDR was 9.22% (95% CI: 8.3%- 10.2%). 
Conclusion: Our study showed that M. tuberculosis LAM family is prevalent in Europian 
countries. LAM sub lineage was a major focus of studies that carried out in different countries. 
The proper technique for prevention of transmission of M. tuberculosis is necessary.  
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Tuberculosis (TB) is a bacterial infectious 
disease caused by Mycobacterium 
tuberculosis      (M. tuberculosis).It is still 
an important cause of morbidity and 
mortality (1, 2).  TB can be seen in various 
forms including pulmonary and extra 
pulmonary (3). Epidemiological estimates 
in 2011 showed 1.4 million deaths and 8.7 
million new cases of TB in world (4). For 
example, reports in Moscow showed M. 
tuberculosis morbidity about 50 cases per 
100,000 people in 2008 (5). The best way 
to treat TB is antibiotic treatment. 
Antibiotics used to treat including first-line 
drugs (isoniazid, rifampin, ethambutol, and 
streptomycin) and second-line drugs 
(aminoglycosides, kanamycin, amikacin, 
and fluoroquinolones) (6-9). The dramatic 
rise and the increasing emergence of drug-
resistant M. tuberculosis isolates are causes 
for concern attention to this disease (10-13). 
Many reports presented multi-drug 
resistance (MDR) -M. tuberculosis that 
resistant to at least both isoniazid and 
rifampin. This problem cause TB, 
increasing treatment period, rising health 
care costs, and mortality rates (14-16). Also 
studies showed that transmission of 
different M. tuberculosis families are 
associated with drug resistance in 
worldwide populations. The main genotype 
families of M. tuberculosis are beijing, 
haarlem, east-african-indian(EAI), 
latinamerican and mediterranean(LAM), U 
and T strains (9, 10). LAM is one of M. 
tuberculosis phylogenetic family and its 
name is derived from the geographical area 
which was isolated. LAM sub lineage was 
a major focus of studies in different area of 
Americas, Europe, Africa and Russia (11). 
Different studies reported MDR-M. 
tuberculosis among M. tuberculosis LAM 
family; Ignatova et al. in Russia reported 
that members of the LAM families were 
MDR in the populations that were studied 
(17). In other study,Valcheva et al. in 
Bulgaria showed that a higher MDR rate 
among LAM families (18). Dymova et al. 
in Russian using variable number tandem 
repeat (VNTR) and restriction fragment 
length polymorphism (RFLP) - insertion 
sequence (IS) 6110-typing showed that, in 
M. tuberculosisisolates that were isolated 
from 98 TB patients, 75 different genetic 
profiles were detected. Also an association 
was observed between the LAM strain 
family and MDR (19, 20). Therefore, 
control and MDR patient's detection are 
required for TB treatment. The aim of our 
study is a survey on prevalence and 
occurrence rate of M. tuberculosis LAM 
family with MDR during 10 years among 
different countries, based on a systematic 
review and meta-analysis. It may be helpful 
in prevention and control of M. tuberculosis 
LAM family with MDR in the world 
population. 
Materials and methods 
Data Sources: For prevalence 
determination of M. tuberculosis LAM 
family with MDR and occurrence rate in the 
worldwide population, literature databases 
(PubMed, Science Direct, Google Scholar, 
ISI Web of Science, and Biological 
Abstracts) and original articles were 
considered between 2001-2012 years in 
English language. Key words for search in 
databases were M. tuberculosis, TB, LAM 
family and MDR. 
Study Selection: Process for selecting the 
studies: the data includes number of cases, 
websites, author, study place, year of the 
research, sample size, and prevalence of 
LAM and MDR association. Inclusion 
criteria were: (1) research articles with full 
text, (2) articles with abstract in English. 
Excluded studies were: (1) review articles, 
(2) congress abstracts, (3) studies that 
reported in languages other than English, 
(4) studies that were not available for us in 
abstract or full text, (5) studies that their 
sampling location was uncertain, (6) studies 
that locations of sampling was performed at 
the same time, and (7) studies that their data 
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Data Extraction: In our study 106 articles 
were selected. The variance of prevalence 
was computed using binomial distribution 
and meta-analysis with the random effect 
model which was applied to combine the 
prevalence among the studies. There was 
sensitivity and heterogeneity among the 
studies. Inconsistency (I²), (95% 
confidence interval, CI) and Cochran Q 
(P<0.10) statistical tests were used to check 
out this heterogeneity. Meta R Version 2.13 
software package for Meta-analysis was 
applied. 
Results  
68 original articles (published 2001 to 
2012) were reviewed from 106 original 
articles.  The total population that was 
obtained from articles in this meta-analysis 
was 25501 (Table 1). According to the 
countries and the years, the highest 
prevalence rate of M. tuberculosis LAM 
family was in Venezuela in 2006 and the 
lowest rate was in Pakistan and Iran in 2010 
and 2006 (both 0.2 %), respectively Also 
patients with MDR -TB were observed in 
these studies (Table 1)  
Prevalence of M. tuberculosis LAM 
family in Worldwide Population Based 
on Years of Study: The data for 10 groups 
were analyzed during 2001-2012. The 
lowest rate of prevalence was observed in 
2010 and 2006 [6.42% (95% CI: 5.91%-
6.95%)]. Highest prevalence rate was in 
2012 [20.62% (95% CI: 17.48%- 24.05%)]. 
In this heterogeneity, I²= 97.7, Chi-squared 
= 383. 86, degrees of freedom (df) = 9 with 
P < 0.00 and between-study variance (tau-
squared) = 0.01 with P= 0.00 were 
obtained. Also, publication bias result is 
presented in Figure 1 (also, Table 2).
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Table 1. Data that were extracted from published documents about country, year, and prevalence of M. 
tuberculosis Latin American and Mediterranean (LAM) family and multi-drug resistant (MDR).  
References  Country Year Prevalence MDR  References  Country Year Prevalence MDR  
(1) Georgia 2010 18% Yes (18) Tanzania 2006 22% - 
(3) Ghana 2011 1.54% - (36) Turkey 2007 28.60% No 
(5) Guinea 2011 18.12% - (37) Russia 2007 46% No 
(7) Brazil 2011 10.30% - (38) UK 2010 0.80% Yes 
(9) Colombia 2011 49.34% - (39) Italy 2007 11.20% - 
(11) Mozambique 2010 37% - (40) Brazil 2011 55.3% - 
(13) Honduras 2010 55% - (41) Turkey 2007 7.90% - 
(15) Ireland 2010 4.10% - (42) Malawi 2010 51.70% - 
(17) Malawi 2010 44.30% - (43) Turkey 2007 29% - 
(19) Taiwan 2010 2.56% Yes (44) Italy 2009 12.80% - 
(20) Guadeloupe  2006 19.70% - (45) Paraguay 2007 52.3% - 
(21) Poland 2010 13.00% Yes (46) Saudi Arabia 2007 7.2% - 
(22) Iran 2006 0.2% No (47) China 2011 1.1% Yes 
(23) China 2010 0.80% Yes (48) Venezuela 2006 74% - 
(24) Indonesia 2009 6.3% - (49) Colombia 2011 49.34% - 
(25) South Africa 2010 28.80% - (50) Italy 2005 5.2% - 
(26) Myanmar 2009 4.50% Yes (51) Taiwan 2008 5.80% - 
(27) Italy 2010 12.80% - (52) Russia 2004 23.8% - 
(28) Turkey 2009 15% Yes (53) Portugal 2007 51% - 
(29) Russia 2009 17.8% Yes (54) Russia 2004 49.6% - 
(30) South Africa 2000 29.50% No (55) Taiwan 2008 3.80% - 
(31) Venezuela 2009 53% Yes (56) Sweden 2004 8% No 
(32) Japan 2005 2% No (57) Madagascar 2005 6% - 
(33) sough 2008 29.20% No (58)  Turkey 2012 5.30% Yes 
(34) Trinidad  2009 11.40% - (59) Sudan 2011 2.60% - 
(35) Sierra Leone 2008 15.5% Yes (60) Iran 2009 0.45% Yes 
(2) Mexico 2011 14.40% - (61) Mexico 2011 11.60% - 
(4) Pakistan 2010 0.20% - (62) Russia 2011 10.4% - 
(6) Turkey 2010 18.40% - (63) Brazil 2011 55.30% - 
(8) Spain 2009 3% - (64) Venezuela 2007 64% - 
(10) Spain 2008 32.10% - (65) Brazil 2011 36.10% - 
(12) Turkey 2008 22.5 - (66) Russia 2006 44.8% - 
(14) Germany 2007 5.8% - (67) South Africa 2011 33% - 
(16) South Africa 2006 29.20% Yes (68) China 2011 3.6% Yes 
 
Table 2. Pooled sensitivity (CI: 95%) and heterogeneity for M. tuberculosis LAM family in worldwide population 
based on year. 
Stratum Proportion 95% CI % Weights (fixed, random) Year 
1 0.29 0.24; 0.34 1.53; 9.80 2000 
2 0.31 0.28; 0.35 3.05; 10.05 2004 
3 0.05 0.03; 0.07 2.81; 10.03 2005 
4 0.44 0.42; 0.45 14.55; 10.26 2006 
5 0.44 0.21; 0.23 18.32; 10.27 2007 
6 0.16 0.13; 0.19 3.40; 10.08 2008 
7 0.25 0.23;  0.26 15.84; 10.27 2009 
8 0.23 0.22; 0.24 22.35; 10.28 2010 
9 0.16 0.15; 0.17 17.68; 10.27 2011 
10 0.05 0.01; 0.11 0.41; 8.64 2012 
 
 
MDR-TB: MDR -TB prevalence analysis 
showed positive MDR between M. 
tuberculosis LAM family (95% CI: 
10.30%-11.23%). Prevalence for negative 
MDR was 9.22% (95% CI: 8.3%- 10.2%). 
In this heterogeneity, I²= 79.4, Chi squared 
= 9.69, df = 2 with P< 0.00, tau squared = 
0.00 with P= 0.00 were observed. Also, no 









































Figure 1. Results of publication bias for M. tuberculosis LAM family in worldwide population based on year (CI: 
95%). 
Discussion 
Studies proved that MDR in patients with 
TB is related with high mortality (1). In this 
study we survey prevalence and occurrence 
rate of MDR-M. tuberculosis LAM family 
during 10 years between world population 
according to a systematic review and meta-
analysis. Results in this study showed that 
lowest and highest rates of M. tuberculosis 
LAM family prevalence were in 2010 (0.2 
%) and 2006 (0.2 %), and 2006 (74%), 
respectively. Also a transmission of this 
family was observed in our study during 10 
years among 36 countries. Dye et al. in 
2009 in Switzerland reported that estimated 
global TB incidence was 63% during 1997–
2006 between 211 countries (68). Different 
factors can   affect TB occurrence rate in 
countries. These factors including poor 
living conditions, cigarette smoking, 
diabetes, chronic peritoneal dialysis, MDR-
TB, imprisonment, HIV infection, alcohol 
abuse, and air pollution (69).Jagielski et al. 
in 2009 in France reported that MDR strains 
(13%) were detected in 27 patients with TB 
(70). Also Durmaz et al. in Turkey in 2007 
showed MDR in clinical isolates of M. 
tuberculosis of T super-family (29%), 
LAM (33.5%), Haarlem (14%), and S 
lineage (3%) (71). MDR positive in 
different countries in our study was 
observed. Also negative MDR was 9.22%. 
Different factors such as spread of MDR-
TB strains, acquired resistance during 
resistance gene transmission in patients and 
geographical distribution among 
neighboring countries are important factors 
for MDR-TB different rates in studies. Also 
genetic variation is related to prevalence 
and spread of drug-resistant strains. So 
genotyping is an important tool for 
detection of origin and transmission 
patterns of drug-resistant strains (72). There 
are several methods for molecular typing of 
M. tuberculosis such as: Spoligotyping, 
RFLP typing based on the IS6110 and 
VNTR (6 -8). Spoligotyping is a major 
technical for molecular typing of M. 
tuberculosis (70). This typing method is 
based on DNA presence of polymorphism 
at one particular chromosomal locus, the 
"Direct Repeat" (DR) region, which is in M. 
tuberculosis complex bacteria (7). The DR 
locus consists of conserved direct 
repeatations interspersed with unique 
spacer sequences (8). Therefore we study 
LAM family prevalence and occurrence 
rate by spoligotyping method. Association 
between LAM family and MDR in articles 
that obtained in different countries was 
observed. In a study in 2014 in Iraq, Ahmed 
et al. with spoligotyping yielded 39 patterns 
among 270 isolates from 134 patients. In 
Ahmed's study, 70 isolates were found as 
MDR (73). Imperiale et al. in 2013 in 
Argentina by spoligotyping showed that 
Haarlem, LAM and T family were the main 
Bias assessment plot
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spoligotyping families and katG315 gene 
mutation was mainly associated with LAM 
family (74). Resistance to drugs in M. 
tuberculosis families may be associated 
with MDR and different among various 
families (69). In our meta-analysis different 
original article obtained from PubMed, 
Science Direct, Google Scholar, Biological 
Abstracts, and ISI web of knowledge in 
Thomson Reuters with regard to prevalence 
of LAM family in world population. In this 
review, we use statistical analysis and 
proved association drug resistance in total 
published reports. MDR -M. tuberculosis 
families can be found in different countries, 
so an outbreak of MDR-TB in populations 
can be occurred. A program for detection 
and prevention of MDR-M. tuberculosis 
family's transmission is necessary (69, 75). 
It is hoped this systematic review and meta-
analysis can be effective on control, 
prevention of transmission, origin detection 
of LAM Family and its control. 
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